Why MIRA Pharmaceuticals is targeting chemotherapy-induced nerve pain with Ketamir-2
Find out how MIRA Pharmaceuticals aims to transform CIPN care with Ketamir-2 and why regulators and investors are watching its 2026 development milestones.
Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
Relay Therapeutics secures FDA breakthrough designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer
FDA grants breakthrough therapy designation to Relay Therapeutics’ zovegalisib. Find out what this changes for PI3K-mutant breast cancer treatment.
How Prelude Therapeutics is advancing a JAK2 JH2 strategy into the clinic after FDA IND clearance
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.
What Theriva Biologics’ APAO 2026 presentation signals for intravitreal oncology treatments
Theriva’s APAO 2026 VCN-01 data reveals how viral synergy and local delivery could redefine pediatric eye cancer care.
Could Invivyd’s VYD2311 offer a safer alternative to mRNA COVID vaccines for vulnerable groups?
Invivyd’s LIBERTY trial could reshape COVID prophylaxis by comparing VYD2311 antibody safety with mRNA vaccines. See what’s at stake for regulators.
WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.
Why the SRS–Lenke–Aubin 3D classification could reshape adolescent scoliosis research
The SRS–Lenke–Aubin 3D classification brings new depth to AIS care. Find out how it could reshape surgery, planning, and clinical trial design.
CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates
CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.